Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T17:57:57.151Z.
Calculation as of: 2026-10-06T17:57:57.151Z.
Quote observation: 2026-10-06T17:55:14.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 833b8a33f5e3aa548e06775940c7a83493d9a3083fc648ecb3f8ecd80d633b38
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
Market Cap
$247.63M
EV/EBITDA Ratio
N/A
TTM Avg
70.15x
3Y Avg
225.61x
5Y Avg
165.39x
Market Cap
$246.26M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$243.73M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$242.50M
EV/EBITDA Ratio
N/A
TTM Avg
28.93x
3Y Avg
31.09x
5Y Avg
27.66x
Market Cap
$242.54M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$241.04M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$255.95M
EV/EBITDA Ratio
473.19x
TTM Avg
197.45x
3Y Avg
157.93x
5Y Avg
101.85x
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Quantum-Si incorporated (QSI) | $248.27M | N/A | N/A | N/A | N/A |
| Upstream Bio, Inc. (UPB)vs › | $248.43M | N/A | N/A | N/A | N/A |
| Sol-Gel Technologies Ltd. (SLGL)vs › | $247.63M | N/A | 70.15x | 225.61x | 165.39x |
| Century Therapeutics, Inc. (IPSC)vs › | $246.26M | N/A | N/A | N/A | N/A |
| Greenwich LifeSciences, Inc. (GLSI)vs › | $243.73M | N/A | N/A | N/A | N/A |
| Lifecore Biomedical, Inc. (LFCR)vs › | $242.50M | N/A | 28.93x | 31.09x | 27.66x |
| CAMP4 Therapeutics Corporation (CAMP)vs › | $242.54M | N/A | N/A | N/A | N/A |
| Galectin Therapeutics Inc. (GALT)vs › | $241.04M | N/A | N/A | N/A | N/A |
| Anika Therapeutics, Inc. (ANIK)vs › | $255.95M | 473.19x | 197.45x | 157.93x | 101.85x |
| Q32 Bio Inc. (QTTB)vs › | $238.71M | 6.29x | 4.45x | 4.45x | 4.45x |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
